Ranked #5,065 of 8,699 institutional investors
Euclidean Capital LLC
New York, NY
$291M
US stock portfolio at live prices · today −$3.8M (−1.30%)
Market closed. Prices as of Nov 20, 8:41 AM ET
- Value at quarter end (Q3 2026)
- $324M
- Change from Q2 2026
- −$116.2M (−26.42%)
- Positions
- 10 · 1 new, 1 sold out
- Filed
- Nov 16, 2026
Holdings
Q3 2026 13F, live pricesVEU 85.0%INDA 6.60%ORIC 2.62%TMS 1.57%PMVP 1.18%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| VEU Vanguard FTSE All-World ex-US Index Fund ETF Shares | 3,243,484 | $247M | 85.0% | Unchanged |
| INDA iShares MSCI India ETF | 369,600 | $19.2M | 6.60% | Unchanged |
| ORIC ORIC Pharmaceuticals, Inc. | 989,410 | $7.6M | 2.62% | Unchanged |
| TMS Teamshares Inc. | 1,099,974 | $4.6M | 1.57% | Unchanged |
| PMVP PMV Pharmaceuticals, Inc. | 2,627,643 | $3.4M | 1.18% | Unchanged |
| ALEC Alector, Inc. | 1,307,858 | $3.0M | 1.03% | Unchanged |
| FHTX Foghorn Therapeutics Inc. | 1,573,761 | $2.8M | 0.96% | Unchanged |
| SRZN Surrozen, Inc. | 87,696 | $2.7M | 0.92% | Unchanged |
| TNYA Tenaya Therapeutics, Inc. | 1,015,705 | $303K | 0.10% | Unchanged |
| MRLN Merlin, Inc. | 47,610 | $42K | <0.1% | New |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| VTV Vanguard Morningstar Value ETF | 520,000 | $113M |